(688277)"Tinavi Medical Technologies Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688277 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates that the company experienced a decline in total revenue compared to the previous year, alongside significant net losses attributed to various operational costs. It also highlights a decrease in research and development expenditure as a percentage of revenue, reflecting changes in operational focus during the quarter. The report confirms that the financial statements have not been audited, and it includes a summary of the company's assets and liabilities as of the reporting date.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Tinavi Medical Technologies Co., Ltd. on 6ix
Earlier from Tinavi Medical Technologies
- (688277)"Tinavi Medical Technologies Co., Ltd."Announcement on Progress of Share Issuance for Asset Acquisition and Raising of Supporting Funds and Related Party Transaction
- (688277)"Tinavi Medical Technologies Co., Ltd."Announcement on Increase in Estimated Amount of Routine Related Party Transactions for 2026
- (688277)"Tinavi Medical Technologies Co., Ltd."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executives and Securities Affairs Representative
- (688277)"Tinavi Medical Technologies Co., Ltd."Announcement on Appointment of Board Secretary
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Later from Tinavi Medical Technologies
All Tinavi Medical Technologies news releasesFollow Tinavi Medical Technologies into a list and get an email when it puts out news.
Follow Tinavi Medical Technologies